385 related articles for article (PubMed ID: 18814983)
1. Positron Emission Tomography (PET) and breast cancer in clinical practice.
Lavayssière R; Cabée AE; Filmont JE
Eur J Radiol; 2009 Jan; 69(1):50-8. PubMed ID: 18814983
[TBL] [Abstract][Full Text] [Related]
2. A preliminary report of breast cancer screening by positron emission mammography.
Yamamoto Y; Tasaki Y; Kuwada Y; Ozawa Y; Inoue T
Ann Nucl Med; 2016 Feb; 30(2):130-7. PubMed ID: 26586370
[TBL] [Abstract][Full Text] [Related]
3. The current status of positron emission mammography in breast cancer diagnosis.
Kalles V; Zografos GC; Provatopoulou X; Koulocheri D; Gounaris A
Breast Cancer; 2013 Apr; 20(2):123-30. PubMed ID: 23239242
[TBL] [Abstract][Full Text] [Related]
4. FDG PET and PET/CT.
Krause BJ; Schwarzenböck S; Souvatzoglou M
Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
[TBL] [Abstract][Full Text] [Related]
5. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
7. FDG PET, PET/CT, and breast cancer imaging.
Rosen EL; Eubank WB; Mankoff DA
Radiographics; 2007 Oct; 27 Suppl 1():S215-29. PubMed ID: 18180228
[TBL] [Abstract][Full Text] [Related]
8. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
Buscombe JR; Holloway B; Roche N; Bombardieri E
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
[TBL] [Abstract][Full Text] [Related]
9. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
10. Screening for cancer with PET and PET/CT: potential and limitations.
Schöder H; Gönen M
J Nucl Med; 2007 Jan; 48 Suppl 1():4S-18S. PubMed ID: 17204716
[TBL] [Abstract][Full Text] [Related]
11. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.
Berg WA; Weinberg IN; Narayanan D; Lobrano ME; Ross E; Amodei L; Tafra L; Adler LP; Uddo J; Stein W; Levine EA;
Breast J; 2006; 12(4):309-23. PubMed ID: 16848840
[TBL] [Abstract][Full Text] [Related]
12. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
13. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
16. Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer.
Tafra L; Cheng Z; Uddo J; Lobrano MB; Stein W; Berg WA; Levine E; Weinberg IN; Narayanan D; Ross E; Beylin D; Yarnall S; Keen R; Sawyer K; Van Geffen J; Freimanis RL; Staab E; Adler LP; Lovelace J; Shen P; Stewart J; Dolinsky S
Am J Surg; 2005 Oct; 190(4):628-32. PubMed ID: 16164937
[TBL] [Abstract][Full Text] [Related]
17. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]